Skip to Content


In the US, Inlyta (axitinib systemic) is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Renal Cell Carcinoma.

US matches:

UK matches:

Ingredient matches for Inlyta


Axitinib is reported as an ingredient of Inlyta in the following countries:

  • Australia
  • Austria
  • Belgium
  • Bosnia & Herzegowina
  • Canada
  • Chile
  • Croatia (Hrvatska)
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong
  • Hungary
  • Iceland
  • Ireland
  • Israel
  • Italy
  • Japan
  • Lithuania
  • Malaysia
  • New Zealand
  • Norway
  • Poland
  • Romania
  • Singapore
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.